PharmaEngine - Asset Resilience Ratio

Latest as of September 2025: 62.91%

PharmaEngine (4162) has an Asset Resilience Ratio of 62.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 4162 total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

NT$3.09 Billion

≈ $97.27 Million USD Cash + Short-term Investments

Total Assets

NT$4.91 Billion

≈ $154.62 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2009–2024)

This chart shows how PharmaEngine's Asset Resilience Ratio has changed over time. See 4162 book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down PharmaEngine's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PharmaEngine market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$3.09 Billion	62.91%
Total Liquid Assets	NT$3.09 Billion	62.91%

Asset Resilience Insights

Very High Liquidity: PharmaEngine maintains exceptional liquid asset reserves at 62.91% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

PharmaEngine Industry Peers by Asset Resilience Ratio

Compare PharmaEngine's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for PharmaEngine (2009–2024)

The table below shows the annual Asset Resilience Ratio data for PharmaEngine.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	49.03%	NT$2.87 Billion ≈ $90.33 Million	NT$5.85 Billion ≈ $184.24 Million	-20.58pp
2023-12-31	69.61%	NT$2.75 Billion ≈ $86.72 Million	NT$3.95 Billion ≈ $124.57 Million	+21.90pp
2022-12-31	47.71%	NT$1.89 Billion ≈ $59.62 Million	NT$3.97 Billion ≈ $124.97 Million	+6.41pp
2021-12-31	41.30%	NT$1.66 Billion ≈ $52.39 Million	NT$4.03 Billion ≈ $126.85 Million	+4.27pp
2020-12-31	37.03%	NT$1.56 Billion ≈ $49.09 Million	NT$4.21 Billion ≈ $132.54 Million	-54.17pp
2019-12-31	91.20%	NT$3.32 Billion ≈ $104.69 Million	NT$3.64 Billion ≈ $114.79 Million	+5.30pp
2018-12-31	85.90%	NT$3.30 Billion ≈ $104.11 Million	NT$3.85 Billion ≈ $121.19 Million	+20.16pp
2017-12-31	65.74%	NT$2.70 Billion ≈ $85.15 Million	NT$4.11 Billion ≈ $129.52 Million	+13.52pp
2016-12-31	52.23%	NT$2.07 Billion ≈ $65.14 Million	NT$3.96 Billion ≈ $124.74 Million	-31.76pp
2015-12-31	83.98%	NT$2.72 Billion ≈ $85.69 Million	NT$3.24 Billion ≈ $102.03 Million	+79.02pp
2010-12-31	4.96%	NT$4.72 Million ≈ $148.86K	NT$95.27 Million ≈ $3.00 Million	-50.08pp
2009-12-31	55.04%	NT$23.00 Million ≈ $724.63K	NT$41.79 Million ≈ $1.32 Million	--

pp = percentage points

About PharmaEngine

TWO:4162 Taiwan Biotechnology

Market Cap

$245.05 Million

NT$7.78 Billion TWD

Market Cap Rank

#15764 Global

#712 in Taiwan

Share Price

NT$54.90

Change (1 day)

+0.37%

52-Week Range

NT$53.80 - NT$92.50

All Time High

NT$178.54